$13.52 million received! Hutchison China MediTech (01512.HK) received milestone payment for the first prescription payment of Merck Serono's BeiGene in China and Q1 2026 sales share.

According to the Wise Financial APP, on June 9, 2026, Haoyu Pharmaceuticals (02256.HK) announced that the company has received a payment of $13.52 million from Merck. The payment includes a milestone payment triggered by the first prescription of Pemigatinib (Pemigatinib Hydrochloride Capsules) in China, as well as sales royalties for the first quarter of 2026, which will be recognized as revenue for the company in 2026.